SCHEMBL16189596

SCHEMBL16189596

Cc1nccc2cccc(-c3ccc(-c4ccc(-c5nc(-c6ccccc6)nc(-c6ccccc6)n5)cc4)cc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
CYP2A6 P11509 1/20 0.41
TNF P01375 1/20 0.40
CHEK1 O14757 1/20 0.39
MAOA P21397 1/20 0.38
LMNA P02545 1/20 0.37
KCNH2 Q12809 2/20 0.36
KCNA5 P22460 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35
LCK P06239 1/20 0.35
FYN P06241 1/20 0.35
IGF1R P08069 1/20 0.35
LTK P29376 1/20 0.35
KDR P35968 1/20 0.35
MAP2K2 P36507 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16189054 0.95 L3MBTL1 (0.39) L3MBTL1CYP2A6TNFCHEK1MAOA
SCHEMBL21034053 0.91 CYP2A6 (0.48) L3MBTL1CYP2A6TNFCHEK1MAOA
SCHEMBL17655896 0.82 ALDH1A1 (0.48) L3MBTL1TNFLMNAMAPK9CLK4
SCHEMBL16189301 0.81 CYP2A6 (0.46) L3MBTL1CYP2A6TNFMAOALMNA
SCHEMBL16716533 0.81 ALDH1A1 (0.50) L3MBTL1TNFLMNAMAPK9CLK4
SCHEMBL16716596 0.80 L3MBTL1 (0.50) L3MBTL1LMNAMEN1ALDH1A1MAPT
SCHEMBL16189413 0.80 MKNK1 (0.55) L3MBTL1LMNAMKNK1MKNK2MEN1
SCHEMBL27455783 0.79 ALDH1A1 (0.45) L3MBTL1TNFLMNAKCNH2KCNA5
SCHEMBL17829272 0.78 SMN1; SMN2 (0.50) L3MBTL1TNFLMNAKCNH2KCNA5
SCHEMBL16189062 0.78 MKNK1 (0.57) L3MBTL1LMNAMKNK1MKNK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
WO-2014171541-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE ELEMENT AND APPLICATION THEREFOR 東ソー株式会社 (JP) 2014-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 L3MBTL1 997/4885CYP2A6 3145/4885TNF 4572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.